Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Orthostatic hypotension in a patient with Shy-Drager syndrome was treated for 6 months with oral DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS). Adrenergic function was evaluated before and during treatment by measurements of changes in blood pressure and plasma norepinephrine on head-up tilting and by the response of blood pressure to the Valsalva maneuver and infused norepinephrine. After the patient received DL-threo-DOPS, the fall in his mean arterial blood pressure on head-up tilting was reduced and he had no syncope when standing. When peripheral decarboxylase inhibitor was combined with DL-threo-DOPS, the same beneficial effect on orthostatic hypotension was observed.
D001342:Autonomic Nervous System Diseases / Q000150:complications*; D001794:Blood Pressure / Q000187:drug effects; D002230:Carbidopa / Q000627:therapeutic use; D015103:Droxidopa / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D007024:Hypotension, Orthostatic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood / Q000627:therapeutic use; D010656:Phenylephrine / Q000627:therapeutic use; D012694:Serine / Q000031:analogs & derivatives*; D012791:Shy-Drager Syndrome / Q000150:complications*; D014636:Valsalva Maneuver
D004338:Drug Combinations; D010656:Phenylephrine; D012694:Serine; D015103:Droxidopa; D002230:Carbidopa; D009638:Norepinephrine